tetano
Editor, Senior Moderator
Eur J Immunol
. 2021 Mar 27.
doi: 10.1002/eji.202149167. Online ahead of print.
A Single Subcutaneous or Intranasal Immunization with Adenovirus-Based SARS-CoV-2 Vaccine Induces Robust Humoral and Cellular Immune Responses in Mice
Eun Kim[SUP] 1 [/SUP], Florian J Weisel[SUP] 2 [/SUP], Stephen C Balmert[SUP] 3 [/SUP], Muhammad S Khan[SUP] 1 4 [/SUP], Shaohua Huang[SUP] 1 [/SUP], Geza Erdos[SUP] 3 [/SUP], Thomas W Kenniston[SUP] 1 [/SUP], Cara Donahue Carey[SUP] 3 [/SUP], Stephen M Joachim[SUP] 2 [/SUP], Laura J Conter[SUP] 2 [/SUP], Nadine M Weisel[SUP] 2 [/SUP], Nisreen M A Okba[SUP] 5 [/SUP], Bart L Haagmans[SUP] 5 [/SUP], Elena Percivalle[SUP] 6 [/SUP], Irene Cassaniti[SUP] 6 [/SUP], Fausto Baldanti[SUP] 6 7 [/SUP], Emrullah Korkmaz[SUP] 3 8 [/SUP], Mark J Shlomchik[SUP] 2 [/SUP], Louis D Falo Jr[SUP] 3 8 9 10 11 [/SUP], Andrea Gambotto[SUP] 1 4 11 12 13 [/SUP]
Affiliations
Abstract
Optimal vaccines are needed for sustained suppression of SARS-CoV-2 and other novel coronaviruses. Here, we developed a recombinant type 5 adenovirus vector encoding the gene for the SARS-CoV-2 S1 subunit antigen (Ad5.SARS-CoV-2-S1) for COVID-19 immunization and evaluated its immunogenicity in mice. A single immunization with Ad5.SARS-CoV-2-S1 via S.C. injection or I.N delivery induced robust antibody and cellular immune responses. Vaccination elicited significant S1-specific IgG, IgG1, and IgG2a endpoint titers as early as 2 weeks and the induced antibodies were long-lasting. I.N. and S.C. administration of Ad5.SARS-CoV-2-S1 produced S1-specific germinal center B cells in cervical and axillary lymph nodes, respectively. Moreover, I.N. and S.C. immunization evoked significantly greater antigen-specific T-cell responses compared to unimmunized control groups with indications that S.C. injection was more effective than I.N. delivery in eliciting cellular immune responses. Mice vaccinated by either route demonstrated significantly increased virus-specific neutralization antibodies on Week 8 and Week 12 compared to control groups, as well as bone marrow AFC, indicative of long-term immunity. Thus, this Ad5-vectored SARS-CoV-2 vaccine candidate showed promising immunogenicity following delivery to mice by S.C. and I.N. routes of administration, supporting the further development of Ad-based vaccines against COVID-19 and other infectious diseases for sustainable global immunization programs. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Recombinant DNA vaccines; SARS-CoV-2; adenovirus; infectious diseases.
. 2021 Mar 27.
doi: 10.1002/eji.202149167. Online ahead of print.
A Single Subcutaneous or Intranasal Immunization with Adenovirus-Based SARS-CoV-2 Vaccine Induces Robust Humoral and Cellular Immune Responses in Mice
Eun Kim[SUP] 1 [/SUP], Florian J Weisel[SUP] 2 [/SUP], Stephen C Balmert[SUP] 3 [/SUP], Muhammad S Khan[SUP] 1 4 [/SUP], Shaohua Huang[SUP] 1 [/SUP], Geza Erdos[SUP] 3 [/SUP], Thomas W Kenniston[SUP] 1 [/SUP], Cara Donahue Carey[SUP] 3 [/SUP], Stephen M Joachim[SUP] 2 [/SUP], Laura J Conter[SUP] 2 [/SUP], Nadine M Weisel[SUP] 2 [/SUP], Nisreen M A Okba[SUP] 5 [/SUP], Bart L Haagmans[SUP] 5 [/SUP], Elena Percivalle[SUP] 6 [/SUP], Irene Cassaniti[SUP] 6 [/SUP], Fausto Baldanti[SUP] 6 7 [/SUP], Emrullah Korkmaz[SUP] 3 8 [/SUP], Mark J Shlomchik[SUP] 2 [/SUP], Louis D Falo Jr[SUP] 3 8 9 10 11 [/SUP], Andrea Gambotto[SUP] 1 4 11 12 13 [/SUP]
Affiliations
- PMID: 33772778
- DOI: 10.1002/eji.202149167
Abstract
Optimal vaccines are needed for sustained suppression of SARS-CoV-2 and other novel coronaviruses. Here, we developed a recombinant type 5 adenovirus vector encoding the gene for the SARS-CoV-2 S1 subunit antigen (Ad5.SARS-CoV-2-S1) for COVID-19 immunization and evaluated its immunogenicity in mice. A single immunization with Ad5.SARS-CoV-2-S1 via S.C. injection or I.N delivery induced robust antibody and cellular immune responses. Vaccination elicited significant S1-specific IgG, IgG1, and IgG2a endpoint titers as early as 2 weeks and the induced antibodies were long-lasting. I.N. and S.C. administration of Ad5.SARS-CoV-2-S1 produced S1-specific germinal center B cells in cervical and axillary lymph nodes, respectively. Moreover, I.N. and S.C. immunization evoked significantly greater antigen-specific T-cell responses compared to unimmunized control groups with indications that S.C. injection was more effective than I.N. delivery in eliciting cellular immune responses. Mice vaccinated by either route demonstrated significantly increased virus-specific neutralization antibodies on Week 8 and Week 12 compared to control groups, as well as bone marrow AFC, indicative of long-term immunity. Thus, this Ad5-vectored SARS-CoV-2 vaccine candidate showed promising immunogenicity following delivery to mice by S.C. and I.N. routes of administration, supporting the further development of Ad-based vaccines against COVID-19 and other infectious diseases for sustainable global immunization programs. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Recombinant DNA vaccines; SARS-CoV-2; adenovirus; infectious diseases.